Sequential evaluation of hepatic functional reserve by<sup>99m</sup>Technetium-galactosyl human serum albumin scinitigraphy after proton beam therapy: a report of three cases and a review of the literatures

Igaki, Hiroshi; Tokuuye, Koichi; Takeda, Takeshi; Sugahara, Shinji; Hata, Masaharu; Hashimoto, Takayuki; Fukumitsu, Nobuyoshi; Wu, Jin; Ohnishi, Kayoko; Ohara, Kiyoshi; Akine, Yasuyuki

doi:10.1080/02841860600690347

Cited by 3 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metastatic liver tumors are significantly more common than primary liver cancer and are difficult to cure despite various treatment approaches [5,6] . Although surgical resection is the current standard treatment for metastatic liver tumors, other treatments such as proton beam radiotherapy, immunotherapy have been applied for hepatocellular carcinoma and metastatic liver tumor [7][8][9][10][11]. However, treatment options are updated year by year, the selection policy for newly developed treatments have not yet been established.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, CIRT has biological advantages because of high linear energy transfer radiation compared to proton beam and X-ray [12][13][14]. CIRT has showed efficacy and safety for the treatment of primary and metastatic liver tumors, even in cases that are considered difficult to manage surgically [7,12,13]. Because many patients with liver tumors have impaired liver function, it is essential to assess the reserve capacity of the liver prior to CIRT in order to accurately estimate the post-therapeutic residual reserve capacity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Estimation of post-therapeutic liver reserve capacity using 99mTc-GSA scintigraphy prior to carbon-ion radiotherapy for liver tumors

Yamazaki

Nishii

Mizutani

et al. 2022

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

diethylenetriaminepentaacetic acid; GSA-RL, GSA-Rmax of the estimated residual liver; GSA-Rmax, maximal removal rate of 99m Tc -GSA; SPECT, single-photon emission computed tomography; 99m Tc-GSA, 99m Tc-galactosyl human serum albumin; VOI, volume of interest Key results:The median GSA-RL was 0.393 [range, 0.057-0.729] mg/min, GSA-Rmax after CIRT was 0.369 [range, 0.037-0.780] mg/min (P = .40).The linear regression equation representing the relationship between the GSA-RL and GSA-Rmax after CIRT was y = 0.05 + 0.84x (R 2 = 0.67, P < .0001). There was a positive correlation between the estimated and actual post-treatment values as well as in the group with impaired liver reserve (R 2 = 0.62, P = .0005).A summary statement: 99m Tc-GSA scintigraphy can be used to accurately estimate liver reserve capacity after carbon-ion radiotherapy in patients with liver tumors regardless of disease severity.Results: Overall, 50 patients were included (mean age ± standard deviation, 73 years ± 11; range, 29-89 years, 35 men). The median GSA-RL was 0.393 [range, 0.057-0.729] mg/min, the median GSA-Rmax after CIRT was 0.369 [range, 0.037-0.780] mg/min (P = .40). The linear regression equation representing the relationship between the GSA-RL and GSA-Rmax after CIRT was y = 0.05 + 0.84x (R 2 = 0.67, P < .0001). There was a positive correlation between the estimated and actual post-treatment values for all patients, as well as in the group with impaired liver reserve capacity (y = -0.02 + 1.09x (R 2 = 0.62, P = .0005)).Conclusions: 99m Tc-GSA scintigraphy has potential clinical utility for estimating the residual liver reserve capacity in patients undergoing carbon-ion radiotherapy for liver tumors. Clinical Trial registration: UMIN000038328, https://center6.umin.ac.jp/cgi-openbin/ctr/ctr_view.cgi?recptno=R000043545

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Estimation of post-therapeutic liver reserve capacity using 99mTc-GSA scintigraphy prior to carbon-ion radiotherapy for liver tumors

Yamazaki

Nishii

Mizutani

et al. 2022

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

Estimation of Post-therapeutic Liver Reserve Capacity Using 99mTc-GSA Scintigraphy Prior to Carbon-ion Radiotherapy for Liver Tumors

Yamazaki

Nishii

Mizutani

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: There is currently no established imaging method for assessing liver reserve capacity prior to carbon-ion radiotherapy (CIRT) for liver tumors. In order to perform safe CIRT, it is essential to estimate the post-therapeutic residual reserve capacity of the liver. Purpose: To evaluate the ability of pre-treatment 99m Tc-GSA scintigraphy to accurately estimate the residual liver reserve capacity in patients treated with CIRT for liver tumors. Materials and Methods: This retrospective study evaluated 50 patients who were performed CIRT for liver tumors between December 2018 and September 2020 and underwent 99m Tc-GSA scintigraphy before and 3 months after CIRT, Gd-EOB-DTPA-enhanced MRI within 1 month before CIRT were evaluated. The maximal removal rate of 99m Tc-GSA (GSA-Rmax) was analyzed for the evaluation of pre-treatment liver reserve capacity. Then, the GSA-Rmax of the estimated residual liver (GSA-RL) was calculated using liver SPECT images fused with the Gd-EOB-DTPA-enhanced MRI. GSA-RL before CIRT and GSA-Rmax at 3 months after CIRT were compared using non-parametric Wilcoxon signed-rank test and linear regression analysis. Results: Overall, 50 patients were included (mean age ± standard deviation, 73 years ± 11; range, 29–89 years, 35 men). The median GSA-RL was 0.393 [range, 0.057–0.729] mg/min, the median GSA-Rmax after CIRT was 0.369 [range, 0.037–0.780] mg/min ( P = .40). The linear regression equation representing the relationship between the GSA-RL and GSA-Rmax after CIRT was y = 0.05 + 0.84x (R 2 = 0.67, P < .0001). There was a positive correlation between the estimated and actual post-treatment values for all patients, as well as in the group with impaired liver reserve capacity (y = - 0.02 + 1.09x (R 2 = 0.62, P = .0005)). Conclusions: 99m Tc-GSA scintigraphy has potential clinical utility for estimating the residual liver reserve capacity in patients undergoing carbon-ion radiotherapy for liver tumors. Clinical Trial registration: UMIN000038328, https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000043545

show abstract

Imaging of normal lung, liver and parotid gland function for radiotherapy

et al. 2010

View full text Add to dashboard Cite

There is growing clinical evidence that functional imaging is useful for target volume definition and early assessment of tumour response to external beam radiotherapy. A subject that has perhaps received less attention, but is no less promising, is the application of functional imaging to the prediction or measurement of radiation adverse effects in normal tissues. In this manuscript, we review the current published literature describing the use of positron emission tomography (PET), four-dimensional computed tomography (4D-CT), single photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI) to study normal tissue function in the context of radiotherapy to the lung, liver and head & neck. Published results to date demonstrate that functional imaging can be used to preferentially avoid normal tissues not easily identifiable on solely anatomical images. It is also a potentially very powerful tool for the early detection of radiotherapy-induced normal tissue adverse effects and could provide valuable data for building predictive models of outcome. However, one of the major challenges to building useful predictive models is that, to date, there are very little data available with combined images of normal function, 3D delivered radiation dose and clinical outcomes. Prospective data collection through well-constructed studies which use established morbidity scores is clearly a priority if significant progress is to be made in this area.

show abstract

Sequential evaluation of hepatic functional reserve by^99mTechnetium-galactosyl human serum albumin scinitigraphy after proton beam therapy: a report of three cases and a review of the literatures

Abstract: Technetium-galactosyl human serum albumin scinitigraphy after proton beam therapy: a report of three cases and a review of the literatures,

Cited by 3 publications

References 23 publications

Estimation of post-therapeutic liver reserve capacity using 99mTc-GSA scintigraphy prior to carbon-ion radiotherapy for liver tumors

Estimation of post-therapeutic liver reserve capacity using 99mTc-GSA scintigraphy prior to carbon-ion radiotherapy for liver tumors

Estimation of Post-therapeutic Liver Reserve Capacity Using 99mTc-GSA Scintigraphy Prior to Carbon-ion Radiotherapy for Liver Tumors

Imaging of normal lung, liver and parotid gland function for radiotherapy

Contact Info

Product

Resources

About

Sequential evaluation of hepatic functional reserve by99mTechnetium-galactosyl human serum albumin scinitigraphy after proton beam therapy: a report of three cases and a review of the literatures

Abstract: Technetium-galactosyl human serum albumin scinitigraphy after proton beam therapy: a report of three cases and a review of the literatures,

Cited by 3 publications

References 23 publications

Estimation of post-therapeutic liver reserve capacity using 99mTc-GSA scintigraphy prior to carbon-ion radiotherapy for liver tumors

Estimation of post-therapeutic liver reserve capacity using 99mTc-GSA scintigraphy prior to carbon-ion radiotherapy for liver tumors

Estimation of Post-therapeutic Liver Reserve Capacity Using 99mTc-GSA Scintigraphy Prior to Carbon-ion Radiotherapy for Liver Tumors

Imaging of normal lung, liver and parotid gland function for radiotherapy

Contact Info

Product

Resources

About

Sequential evaluation of hepatic functional reserve by^99mTechnetium-galactosyl human serum albumin scinitigraphy after proton beam therapy: a report of three cases and a review of the literatures